![\"ImmunityBio,](\"https:\/\/www.europesays.com\/europe\/wp-content\/uploads\/2026\/04\/cb476156f993620acf6082a4c9033c43.png\")
ImmunityBio, Inc. Price and Consensus <\/p>\nImmunityBio IBRX is moving from a U.S.-led launch to a broader international rollout. Authorizations now span the United States, the United Kingdom, the European Union, Saudi Arabia, and Macau, covering about 34 countries and territories. The next phase is converting those clearances into steady demand.<\/p>\n
Global scale is a familiar differentiator in immuno-oncology. Large-cap peers such as Merck MRK and Bristol Myers Squibb BMY show how market access and execution can amplify a therapy\u2019s reach once approvals expand.<\/p>\n
IBRX Expands Beyond the U.S. With Multiple Authorizations <\/p>\n
With multiple jurisdictions now cleared, attention shifts to early utilization and ordering patterns across new markets. The commercial question is less about adding authorizations and more about building repeatable launch mechanics.<\/p>\n
Because each region has its own procurement and access pathway, \u201ccommercial readiness\u201d can become the gating factor for near-term contribution.<\/p>\n
ImmunityBio Turns Saudi Authorization Into Early Commercial Sales <\/p>\n
Saudi Arabia is the first proof point of speed. On April 21, Anktiva became commercially available, supported by regional partners Biopharma and Cigalah Healthcare.<\/p>\n
The launch included initial patient identification, helping reduce the lag from clearance to use. Saudi authorization covers bladder cancer and lung cancer patients, including Anktiva with checkpoint inhibitors for metastatic non-small cell lung cancer (NSCLC).<\/p>\n
IBRX Gets a Foothold in Asia Through Macau\u2019s Approval <\/p>\n
Macau delivered the company\u2019s first authorization in Asia. The March 20 decision covers Anktiva plus Bacillus Calmette-Gu\u00e9rin (BCG) for BCG-unresponsive carcinoma in situ (CIS) non-muscle-invasive bladder cancer (NMIBC), with or without papillary tumors.<\/p>\n
Outcomes cited from QUILT-3.032 include a 71% complete response rate and a 26.6-month median duration of response, supporting a durability narrative as the company builds an Asian foothold.<\/p>\n
ImmunityBio, Inc. Price and Consensus ImmunityBio, Inc. Price and Consensus <\/p>\n
\u00a0<\/p>\n
ImmunityBio, Inc. price-consensus-chart | ImmunityBio, Inc. Quote<\/p>\n
ImmunityBio\u2019s EU Conditional Nod Creates a Big Market Test <\/p>\n
The European Commission granted conditional marketing authorization on Feb. 16 for Anktiva plus BCG in BCG-unresponsive NMIBC CIS, with or without papillary tumors.<\/p>\n
Coverage includes European Union member states plus Iceland, Norway, and Liechtenstein. The company framed this as the first immunotherapy authorized in Europe for the indication, a \u201cfirst\u201d that can aid awareness as access work begins.<\/p>\n
IBRX Must Navigate Europe\u2019s Country-by-Country Reimbursement <\/p>\n
Europe\u2019s next hurdle is reimbursement country by country. ImmunityBio is prioritizing the \u201cBig 5,\u201d with Germany expected to commercialize first in 2026.<\/p>\n
That structure can slow the revenue ramp even after authorization, since pricing and rollout timelines vary by market.<\/p>\n
ImmunityBio Builds Optionality With Scalable NK Cell Manufacturing <\/p>\n
In March 2026 manufacturing engineering programs, 64 subjects were treated with no procedure-related serious adverse events reported. The company also reported producing up to 5 billion natural killer cells from a single apheresis, enabling multiple doses within 12 days.<\/p>\n
Management\u2019s \u201cWorld Bank of NK Cells\u201d concept is intended to support scalable supply, and phase I combination experience in relapsed or refractory solid tumors reported no serious adverse events.<\/p>\n
IBRX Road Map for the Next Wave of Value-Defining Events <\/p>\n
ImmunityBio expects additional data readouts in non-muscle-invasive bladder cancer studies in the fourth quarter of 2026 and plans a U.S. regulatory filing with the FDA based on those results.<\/p>\n
The phase II BCG-na\u00efve NMIBC CIS study has completed enrollment, with data expected in the fourth quarter of 2026 and a potential U.S. filing by the end of 2026 if results are positive. A resubmitted supplemental biologics license application seeking label expansion for papillary disease keeps another regulatory track active.<\/p>\n
Into early 2026, the share price has tended to respond to upward estimate revisions and execution milestones. That makes launch follow-through and late-2026 readouts central to the next leg of the story.<\/p>\n
IBRX\u2019s Zacks Rank <\/p>\n
ImmunityBio currently carries a Zacks Rank #3 (Hold). You can see\u00a0the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here.<\/p>\n
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report<\/a><\/p>\n Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report<\/a><\/p>\n Merck & Co., Inc. (MRK) : Free Stock Analysis Report<\/a><\/p>\n ImmunityBio, Inc. (IBRX) : Free Stock Analysis Report<\/a><\/p>\n This article originally published on Zacks Investment Research (zacks.com).<\/a><\/p>\n